Ofran 4 mg/5 ml Oral Solution 50 ml bottle
Indication:1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.3. Prevention of nausea and vomiting associated with radiotherapy4. Prevention of postoperative nausea and/or vomitingDosage & Administration:1. Chemotherapy induced nausea & vomiting (CINV): Adult- For highly emetogenic chemotherapy recommended adult oral dosage of Ofran® is 24 mg given as three 8 mg tablets. For moderately emetogenic chemotherapy the oral dose is one 8mg Ofran® (Ondansetron) tablet or 10 ml of Ofran® oral solution twice daily Pediatric patients- for pediatric patients from 4 to 11 years of age the dosage is one 4mg Ofran® tablet or 5ml of Ofran® solution 3 times per day for 1 to 2 days after completion of chemotherapy.2. Radiotherapy induced nausea and vomiting (RINV): Adult- the recommended oral dosage is one 8-mg Ofran® tablet or 10 mL of Ofran® Oral Solution given 3 times a day.3. Post-operative nausea & vomiting (PONV): Adult- the recommended dosage is 16 mg given as two 8 mg Ofran® tablets or 20 ml of Ofran® oral solution 1 hour before induction of anesthesia.Preparation:Ofran® 8 mg Tablet: Each box contains 30 tablets in blister packOfran® Oral Solution: Each bottle contains 50 ml oral solutionOfran® 8 mg IV Injection: Each box contains 6 ampoules in blister pack..
Tk.45.01/=
Ofran 8mg Tablet
Indication:1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.3. Prevention of nausea and vomiting associated with radiotherapy4. Prevention of postoperative nausea and/or vomitingDosage & Administration:1. Chemotherapy induced nausea & vomiting (CINV): Adult- For highly emetogenic chemotherapy recommended adult oral dosage of Ofran® is 24 mg given as three 8 mg tablets. For moderately emetogenic chemotherapy the oral dose is one 8mg Ofran® (Ondansetron) tablet or 10 ml of Ofran® oral solution twice daily Pediatric patients- for pediatric patients from 4 to 11 years of age the dosage is one 4mg Ofran® tablet or 5ml of Ofran® solution 3 times per day for 1 to 2 days after completion of chemotherapy.2. Radiotherapy induced nausea and vomiting (RINV): Adult- the recommended oral dosage is one 8-mg Ofran® tablet or 10 mL of Ofran® Oral Solution given 3 times a day.3. Post-operative nausea & vomiting (PONV): Adult- the recommended dosage is 16 mg given as two 8 mg Ofran® tablets or 20 ml of Ofran® oral solution 1 hour before induction of anesthesia.Preparation:Ofran® 8 mg Tablet: Each box contains 30 tablets in blister packOfran® Oral Solution: Each bottle contains 50 ml oral solutionOfran® 8 mg IV Injection: Each box contains 6 ampoules in blister pack..
Tk.10.07/=
Onaseron 8 Tab
Onaseron 8 TabDescriptionOndansetron is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully characterized, Ondansetron is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether Ondansetron's antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine.Indications1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including Cisplatin >/= 50 mg/m2.2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.3. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.4. Prevention of postoperative nausea and/or vomiting.5. Nausea-vomiting associated with pregnancy6. Nausea-vomiting associated with gastroenteritisDosage & Administration1. Prevention of nausea-vomiting associated with chemotherapy1 a. AdultParenteral: 32 mg single dose infused over 15 minutes by diluting with 50 ml saline (5% dextrose or 0.9% NaCl) 30 minutes before starting chemotherapy. Alternative therapy: Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before the starting chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.Oral: Highly emetogenic cancer chemotherapy: 24 mg (three 8 mg tablet) administered 30 minutes before start of emetogenic chemotherapyModerate emetogenic cancer chemotherapy: 8 mg (one 8 mg tablet) administered 30 minutes before start of emetogenic chemotherapy. A further 8 mg dose should be administered after 8 hours of the first dose. One 8 mg tablet should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.1 b. PediatricParenteral (6 months onwards): Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before starting moderately to highly emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.Oral (4-11 years): 4 mg tablet should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 4 mg tablet should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.2. Prevention of nausea-vomiting associated with radiotherapyAdults/ Geriatric/ Child of 12 years or overThe recommended dose is 8 mg tablet 3 times a day.For total body irradiation: One 8 mg tablet should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.For single high-dose fraction radiotherapy to the abdomen: One 8 mg tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.For daily fractionated radiotherapy to the abdomen: One 8 mg tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day.3. Prevention of post-operative nausea-vomiting3 a. Adults/ Geriatric/ Child of 12 years or overParenteral : Undiluted 4 mg intravenously or intramuscularly immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes. Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgeryOral: 16 mg (two 8 mg tablets) 1 hour before induction of anesthesia.3 b. Pediatric (1 months to12 years)Parenteral : Weighing less than 40 kg: 0.1-mg/kg body weight in a Single dose . Weighing more than 40 kg: 4mg single dose The dose should be immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes.Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery.4. Nausea-vomiting in gastroenteritis4 a. Adult: 8 mg three times daily.4 b. Pediatric (1 month or over): 0.15 mg/kg body weight three times daily.5. Nausea vomiting in pregnancy8 mg (1 tablet) 2-3 times dailyOnaseron ODT administration procedure:Onaseron ODT should be removed from the blister gently. Then it should be immediately placed on top of the tongue where it will dissolve in seconds and swallowed with saliva. Administration with liquid is not necessary.Side EffectsGenerally Ondansetron is well tolerated. However few side effects including headache, diar..
Tk.10.00/=
Onaseron ODT 4mg Tab
Onaseron ODT 4mg TabDescriptionOndansetron is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully characterized, Ondansetron is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether Ondansetron's antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine.Indications1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including Cisplatin >/= 50 mg/m2.2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.3. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.4. Prevention of postoperative nausea and/or vomiting.5. Nausea-vomiting associated with pregnancy6. Nausea-vomiting associated with gastroenteritisDosage & Administration1. Prevention of nausea-vomiting associated with chemotherapy1 a. AdultParenteral: 32 mg single dose infused over 15 minutes by diluting with 50 ml saline (5% dextrose or 0.9% NaCl) 30 minutes before starting chemotherapy. Alternative therapy: Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before the starting chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.Oral: Highly emetogenic cancer chemotherapy: 24 mg (three 8 mg tablet) administered 30 minutes before start of emetogenic chemotherapyModerate emetogenic cancer chemotherapy: 8 mg (one 8 mg tablet) administered 30 minutes before start of emetogenic chemotherapy. A further 8 mg dose should be administered after 8 hours of the first dose. One 8 mg tablet should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.1 b. PediatricParenteral (6 months onwards): Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before starting moderately to highly emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.Oral (4-11 years): 4 mg tablet should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 4 mg tablet should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.2. Prevention of nausea-vomiting associated with radiotherapyAdults/ Geriatric/ Child of 12 years or overThe recommended dose is 8 mg tablet 3 times a day.For total body irradiation: One 8 mg tablet should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.For single high-dose fraction radiotherapy to the abdomen: One 8 mg tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.For daily fractionated radiotherapy to the abdomen: One 8 mg tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day.3. Prevention of post-operative nausea-vomiting3 a. Adults/ Geriatric/ Child of 12 years or overParenteral : Undiluted 4 mg intravenously or intramuscularly immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes. Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgeryOral: 16 mg (two 8 mg tablets) 1 hour before induction of anesthesia.3 b. Pediatric (1 months to12 years)Parenteral : Weighing less than 40 kg: 0.1-mg/kg body weight in a Single dose . Weighing more than 40 kg: 4mg single dose The dose should be immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes.Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery.4. Nausea-vomiting in gastroenteritis4 a. Adult: 8 mg three times daily.4 b. Pediatric (1 month or over): 0.15 mg/kg body weight three times daily.5. Nausea vomiting in pregnancy8 mg (1 tablet) 2-3 times dailyOnaseron ODT administration procedure:Onaseron ODT should be removed from the blister gently. Then it should be immediately placed on top of the tongue where it will dissolve in seconds and swallowed with saliva. Administration with liquid is not necessary.Side EffectsGenerally Ondansetron is well tolerated. However few side effects including headache..
Tk.5.00/=
Onaseron Syp
Onaseron SypDescriptionOndansetron is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully characterized, Ondansetron is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether Ondansetron's antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine.Indications1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including Cisplatin >/= 50 mg/m2.2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.3. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.4. Prevention of postoperative nausea and/or vomiting.5. Nausea-vomiting associated with pregnancy6. Nausea-vomiting associated with gastroenteritisDosage & Administration1. Prevention of nausea-vomiting associated with chemotherapy1 a. AdultParenteral: 32 mg single dose infused over 15 minutes by diluting with 50 ml saline (5% dextrose or 0.9% NaCl) 30 minutes before starting chemotherapy. Alternative therapy: Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before the starting chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.Oral: Highly emetogenic cancer chemotherapy: 24 mg (three 8 mg tablet) administered 30 minutes before start of emetogenic chemotherapyModerate emetogenic cancer chemotherapy: 8 mg (one 8 mg tablet) administered 30 minutes before start of emetogenic chemotherapy. A further 8 mg dose should be administered after 8 hours of the first dose. One 8 mg tablet should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.1 b. PediatricParenteral (6 months onwards): Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before starting moderately to highly emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.Oral (4-11 years): 4 mg tablet should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 4 mg tablet should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.2. Prevention of nausea-vomiting associated with radiotherapyAdults/ Geriatric/ Child of 12 years or overThe recommended dose is 8 mg tablet 3 times a day.For total body irradiation: One 8 mg tablet should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.For single high-dose fraction radiotherapy to the abdomen: One 8 mg tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.For daily fractionated radiotherapy to the abdomen: One 8 mg tablet should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day.3. Prevention of post-operative nausea-vomiting3 a. Adults/ Geriatric/ Child of 12 years or overParenteral : Undiluted 4 mg intravenously or intramuscularly immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes. Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgeryOral: 16 mg (two 8 mg tablets) 1 hour before induction of anesthesia.3 b. Pediatric (1 months to12 years)Parenteral : Weighing less than 40 kg: 0.1-mg/kg body weight in a Single dose . Weighing more than 40 kg: 4mg single dose The dose should be immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes.Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery.4. Nausea-vomiting in gastroenteritis4 a. Adult: 8 mg three times daily.4 b. Pediatric (1 month or over): 0.15 mg/kg body weight three times daily.5. Nausea vomiting in pregnancy8 mg (1 tablet) 2-3 times dailyOnaseron ODT administration procedure:Onaseron ODT should be removed from the blister gently. Then it should be immediately placed on top of the tongue where it will dissolve in seconds and swallowed with saliva. Administration with liquid is not necessary.Side EffectsGenerally Ondansetron is well tolerated. However few side effects including headache, diarrh..
Tk.45.00/=
Onsat 4 Oral Solu Film
Onsat 4Onsat® is an anti-emetic drug. Oral Soluble Film is orally dissolving film designed to be applied on top of the tongue where it will dissolve within 20 seconds. Onsat® OSF does not require water to aid dissolution or swallowing. Each 4mg & 8 mg Onsat® OSF contain Ondansetron Hydrochloride USP equivalent to Ondansetron 4 & 8 mg respectively. Onsat® is indicated for the prevention and treatment of post-operative nausea and vomiting and for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.Dissolves rapidly in the mouth within 4 to 20 secondsEasy to take- Can be taken without waterEasy to carry- Can be taken anytime, anywhereCan be dosed prior to therapy or SurgeryAppropriate for patients who have trouble swallowing tablets or who refuse suppositories Onsat OSF Prescribing Information..
Tk.12.00/=
Onsat 8 Oral Solu Film
Onsat 8Onsat® is an anti-emetic drug. Oral Soluble Film is orally dissolving film designed to be applied on top of the tongue where it will dissolve within 20 seconds. Onsat® OSF does not require water to aid dissolution or swallowing. Each 4mg & 8 mg Onsat® OSF contain Ondansetron Hydrochloride USP equivalent to Ondansetron 4 & 8 mg respectively. Onsat® is indicated for the prevention and treatment of post-operative nausea and vomiting and for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.Dissolves rapidly in the mouth within 4 to 20 secondsEasy to take- Can be taken without waterEasy to carry- Can be taken anytime, anywhereCan be dosed prior to therapy or SurgeryAppropriate for patients who have trouble swallowing tablets or who refuse suppositories Onsat OSF Prescribing Information..
Tk.18.00/=
Onsat 8 tablet
Onsat 8 tablet1. What Onsat is and what it is used for?Ondansetron is used to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.2. Before you take OnsatOndansetron are contraindicated for patients known to have hypersensitivity to the drug.Take special care with OnsatCheck with your doctor before taking this medicine if:Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.The use of ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomitingTaking other medicinesApomorphine- profound hypotension and loss of consciousness.Pregnancy and breast-feedingReproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg per day respectively and have revealed no evidence of impaired fertility or harm to the fetus due to Ondansetron. There are however, no adequate and well controlled studies on a pregnant women. Ondansetron is excreted in the breast milk of rats. So caution should be exercised when Ondansetron is administered to a nursing mother.3. How to take Onsat?Taking this medicineAlways use Onsat exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.If you take more Onsat than you shouldIf you have too much of this medicine, talk to your doctor straight away.If you stop taking OnsatDo not stop taking this medicine without talking to your doctor. You should not stop taking Onsat just because you feel better. This is because the problem may come back or get worse again.If you have any further questions on the use of this product, ask your doctor or pharmacist.4. Possible side effectsLike all medicines, Onsat can cause side effects, although not everybody gets them.The most common adverse drug events (≥5%) in chemotherapy-induced nausea and vomiting and radiotherapy-induced nausea and vomiting trials were: headache, malaise/fatigue, constipation, and diarrhea. The most common adverse event (≥5%) in postoperative nausea and vomiting trials was headache.Tell your doctor if any of the side effects gets serious or lasts longer than a few days, or if you notice any side effects not listed in this leaflet.5. How to store Onsat?Store in a cool and dry place, away from light. Keep out of reach of children Onsat Prescribing Information..
Tk.10.00/=
Onsat Injection
Onsat InjectionOnsat® is an anti-emetic drug. Each ampoule contains Ondansetron Hydrochloride USP equivalent to Ondansetron 2 mg/ml. Onsat® is indicated for the prevention and treatment of post-operative nausea and vomiting and for the management of simple nausea and vomitingPONV (Prevention of nausea and vomiting associated with post operative procedure)Hyperemesis GravidarumSimple nausea and vomiting.Diarrhea associated nausea and vomiting. Onsat Injection Prescribing Information..
Tk.25.00/=
Periset 50 ml Oral Solution
Periset 50 ml Oral SolutionDESCRIPTIONOndansetron is a highly selective 5-HT3 receptor-antagonist. 5-HT3 serotonin receptors are present both peripherally on vagal nerve terminals and centrally in chemoreceptor trigger zone of the postrema. It is not certain whether ondansetron’s antiemetic action in chemotherapy-induced nausea and vomiting is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with the release of serotonin from enterochromaffin cells of the small intestine.COMPOSITIONPeriset 50 ml Oral Solution: Each 5 ml contains Ondansetron HydrochlorideUSP equivalent to Ondansetron 4 mg.INDICATIONS AND USES• The prevention and treatment of Post-operative nausea and vomiting.• The management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. SIDE EFFECTSGenerally Ondansetron is well tolerated. However few side effects including headache, diarrhoea, dizziness and constipation may be seen afterOndansetron is administrated.CONTRAINDICATIONSOndansetron is contraindicated for patients known to have hypersensitivity to the drug.PRECAUTIONSOndansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapyinduced nausea and vomiting may mask a progressive ileus and/or gastric distension.USE IN PREGNANCY & LACTATIONPregnancy: Pregnancy category B.Nursing Mother: It is not known whether Ondansetron is excreted in human milk. So, caution should be exercised when Ondansetron is administered to nursing women.DRUG INTERACTIONSThere is no evidence that Ondansetron either induces or inhibits the metabolism of other drugs commonly coadministered with it. ButOndansetron (HCl) is known to interact with other drugs like Carbamazepine, Phenytoin, Rifampicin and Tramadol.OVERDOSAGEThere is no specific antidote for Ondansetron overdose. Hypertension (andfaintness) occurred in a patient that took 48 mg of Ondansetron. ..
Tk.45.00/=
Periset 8 mg Tablet
Periset 8 mg TabletDESCRIPTIONOndansetron is a highly selective 5-HT3 receptor-antagonist. 5-HT3 serotonin receptors are present both peripherally on vagal nerve terminals and centrally in chemoreceptor trigger zone of the postrema. It is not certain whether ondansetron’s antiemetic action in chemotherapy-induced nausea and vomiting is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with the release of serotonin from enterochromaffin cells of the small intestine.COMPOSITIONPeriset 50 ml Oral Solution: Each 5 ml contains Ondansetron HydrochlorideUSP equivalent to Ondansetron 4 mg.INDICATIONS AND USES• The prevention and treatment of Post-operative nausea and vomiting.• The management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. SIDE EFFECTSGenerally Ondansetron is well tolerated. However few side effects including headache, diarrhoea, dizziness and constipation may be seen afterOndansetron is administrated.CONTRAINDICATIONSOndansetron is contraindicated for patients known to have hypersensitivity to the drug.PRECAUTIONSOndansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapyinduced nausea and vomiting may mask a progressive ileus and/or gastric distension.USE IN PREGNANCY & LACTATIONPregnancy: Pregnancy category B.Nursing Mother: It is not known whether Ondansetron is excreted in human milk. So, caution should be exercised when Ondansetron is administered to nursing women.DRUG INTERACTIONSThere is no evidence that Ondansetron either induces or inhibits the metabolism of other drugs commonly coadministered with it. ButOndansetron (HCl) is known to interact with other drugs like Carbamazepine, Phenytoin, Rifampicin and Tramadol.OVERDOSAGEThere is no specific antidote for Ondansetron overdose. Hypertension (andfaintness) occurred in a patient that took 48 mg of Ondansetron. ..
Tk.10.03/=
Periset 8 mg/4 ml IM/IV Injection
Periset 8 mg/4 ml IM/IV InjectionDESCRIPTIONOndansetron is a highly selective 5-HT3 receptor-antagonist. 5-HT3 serotonin receptors are present both peripherally on vagal nerve terminals and centrally in chemoreceptor trigger zone of the postrema. It is not certain whether ondansetron’s antiemetic action in chemotherapy-induced nausea and vomiting is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with the release of serotonin from enterochromaffin cells of the small intestine.COMPOSITIONPeriset 50 ml Oral Solution: Each 5 ml contains Ondansetron HydrochlorideUSP equivalent to Ondansetron 4 mg.INDICATIONS AND USES• The prevention and treatment of Post-operative nausea and vomiting.• The management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. SIDE EFFECTSGenerally Ondansetron is well tolerated. However few side effects including headache, diarrhoea, dizziness and constipation may be seen afterOndansetron is administrated.CONTRAINDICATIONSOndansetron is contraindicated for patients known to have hypersensitivity to the drug.PRECAUTIONSOndansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapyinduced nausea and vomiting may mask a progressive ileus and/or gastric distension.USE IN PREGNANCY & LACTATIONPregnancy: Pregnancy category B.Nursing Mother: It is not known whether Ondansetron is excreted in human milk. So, caution should be exercised when Ondansetron is administered to nursing women.DRUG INTERACTIONSThere is no evidence that Ondansetron either induces or inhibits the metabolism of other drugs commonly coadministered with it. ButOndansetron (HCl) is known to interact with other drugs like Carbamazepine, Phenytoin, Rifampicin and Tramadol.OVERDOSAGEThere is no specific antidote for Ondansetron overdose. Hypertension (andfaintness) occurred in a patient that took 48 mg of Ondansetron. ..
Tk.30.10/=
